---
title: Psychedelic legalization and regulation debate
videoId: fpwDi8f6TLQ
---

From: [[⁨cleoabram⁩]] <br/> 

The legal status and public perception of psychedelics have undergone dramatic shifts throughout history, from being a focus of medical research to being banned under the [[war_on_drugs_and_its_impact_on_psychedelic_research | War on Drugs]], and now, a resurgence of interest for their potential therapeutic benefits <a class="yt-timestamp" data-t="00:00:40">[00:00:40]</a>. This has led to a significant debate about their legalization and how they should be regulated.

## A Shifting Legal and Perceptual Landscape

In 1955, psychedelics were legal in both the UK and the US and were considered an exciting area of medical research <a class="yt-timestamp" data-t="00:00:40">[00:00:40]</a>. A British Member of Parliament even took a psychedelic on television <a class="yt-timestamp" data-t="00:00:09">[00:00:09]</a>. By the 1980s, this had completely changed with the United States declaring a "[[war_on_drugs_and_its_impact_on_psychedelic_research | War on Drugs]]" <a class="yt-timestamp" data-t="00:00:48">[00:00:48]</a>. Psychedelics were banned, and research became "much darker" <a class="yt-timestamp" data-t="00:00:56">[00:00:56]</a>. For about 40 years, most psychedelics remained illegal <a class="yt-timestamp" data-t="00:01:00">[00:01:00]</a>.

The ban on psychedelics was largely a "socio-political phenomenon" <a class="yt-timestamp" data-t="00:05:36">[00:05:36]</a>. They became associated with counter-culture, leading to their prohibition for research despite a lack of supporting data for extreme danger <a class="yt-timestamp" data-t="00:05:43">[00:05:43]</a>. During this period, research that did occur often supported the government's narrative of extreme danger <a class="yt-timestamp" data-t="00:05:49">[00:05:49]</a>. A notable example is a 2002 Johns Hopkins study, published in *Science*, which claimed ecstasy caused permanent brain damage based on monkey research where 20% of the animals died <a class="yt-timestamp" data-t="00:06:03">[00:06:03]</a>. A year later, the researchers retracted the study, admitting they had accidentally injected the monkeys with methamphetamine instead of ecstasy <a class="yt-timestamp" data-t="00:06:49">[00:06:49]</a>. This misinformed public perception about psychedelics for decades <a class="yt-timestamp" data-t="00:07:05">[00:07:05]</a>.

## Renewed Interest and Scientific Understanding

Recently, the tide has begun to change again, with a "new and growing fight to make psychedelics legal again in the United States" <a class="yt-timestamp" data-t="00:01:05">[00:01:05]</a>. They are once more an "interesting area of study" <a class="yt-timestamp" data-t="00:01:20">[00:01:20]</a>.

> [!INFO] What are Psychedelics?
> The term "psychedelic" comes from Greek words meaning "mind manifesting" <a class="yt-timestamp" data-t="00:03:11">[00:03:11]</a>. They are a broad category of drugs, including "classic psychedelics" like ecstasy, acid, molly, and magic mushrooms, which primarily act on the brain's 2A serotonin receptor <a class="yt-timestamp" data-t="00:02:27">[00:02:27]</a>. MDMA and ketamine are also generally classified under psychedelics but affect the brain differently <a class="yt-timestamp" data-t="00:03:03">[00:03:03]</a>. When people take these drugs, they often experience vivid colors, moving shapes, and intense emotions, with a profound shift in perception of the world and self <a class="yt-timestamp" data-t="00:03:15">[00:03:15]</a>.

Dr. Matthew Johnson, a professor of Psychiatry and Behavioral Sciences at Johns Hopkins, is a leading researcher in this field <a class="yt-timestamp" data-t="00:03:47">[00:03:47]</a>. He has been studying psychedelics and their potential [[potential_health_benefits_and_therapeutic_applications_of_psychedelics | therapeutic applications]] since 2004 <a class="yt-timestamp" data-t="00:04:00">[00:04:00]</a>.

## [[potential_health_benefits_and_therapeutic_applications_of_psychedelics | Potential Health Benefits]] and Therapeutic Applications

The renewed research has generated significant excitement about the potential of psychedelics to treat various conditions <a class="yt-timestamp" data-t="00:07:32">[00:07:32]</a>.

Recent studies suggest:
*   One high dose of psilocybin relieved anxiety and depression in cancer patients for six months <a class="yt-timestamp" data-t="00:07:46">[00:07:46]</a>.
*   Two-thirds of patients treated with MDMA for PTSD no longer experienced the disorder <a class="yt-timestamp" data-t="00:07:54">[00:07:54]</a>.

Researchers are most confident in MDMA for treating PTSD, and psilocybin for alcoholism, smoking cessation, cancer-related distress, and major depressive disorder <a class="yt-timestamp" data-t="00:08:19">[00:08:19]</a>.

The underlying mechanism for these broad benefits is thought to be the drugs' ability to alter conversations between individual brain cells, allowing them to form new connections <a class="yt-timestamp" data-t="00:08:43">[00:08:43]</a>. This "rewires" the brain, potentially "blast[ing] people out of those ruts" characteristic of mental and behavioral disorders <a class="yt-timestamp" data-t="00:08:51">[00:08:51]</a>.

However, it is crucial to note that psychedelics are not for everyone. For individuals with a family history of schizophrenia, research indicates that psychedelics could trigger manic or psychotic episodes <a class="yt-timestamp" data-t="00:09:21">[00:09:21]</a>.

Given that millions struggle with PTSD (13 million people in 2020) and major depressive episodes (8% of adults), the potential for psychedelics to help is a critical question being explored <a class="yt-timestamp" data-t="00:09:51">[00:09:51]</a>.

## The Future of Legalization and Regulation

The current promising research has led to some psychedelics being on the path to FDA approval <a class="yt-timestamp" data-t="00:10:19">[00:10:19]</a>. Dr. Johnson anticipates MDMA could be FDA-approved for PTSD in the US within a year or two, followed by psilocybin a year or two after that <a class="yt-timestamp" data-t="00:10:24">[00:10:24]</a>.

The vision for legalization is distinctly different from recreational cannabis models:

*   **Supervised Medical Model (FDA Path)**: This involves doctors prescribing the medication and licensed therapists supervising the "trip" <a class="yt-timestamp" data-t="00:11:15">[00:11:15]</a>. Patients would visit certified clinics, lie down comfortably, wear an eye mask, listen to music, and undergo their journey under professional supervision <a class="yt-timestamp" data-t="00:11:26">[00:11:26]</a>. The therapeutic component of this process is still being refined <a class="yt-timestamp" data-t="00:11:43">[00:11:43]</a>.
*   **State-Level Supervised Model (Oregon, Colorado)**: States like Oregon and Colorado have legalized psilocybin for use in "healing centers" <a class="yt-timestamp" data-t="00:12:03">[00:12:03]</a>. In these settings, individuals take psilocybin in a supervised environment with a facilitator, though not necessarily a doctor <a class="yt-timestamp" data-t="00:12:13">[00:12:13]</a>. None of these centers are open yet <a class="yt-timestamp" data-t="00:12:18">[00:12:18]</a>.

Currently, the primary focus of scientists and governments is on supervised settings, not recreational access <a class="yt-timestamp" data-t="00:12:32">[00:12:32]</a>. The ultimate goal is to base regulation on "great science," free from "unwarranted fear or hype" <a class="yt-timestamp" data-t="00:12:42">[00:12:42]</a>. The story of psychedelics serves as a cautionary tale of controlling something not fully understood, leading to fear, distrust, and decades of stifled innovation <a class="yt-timestamp" data-t="00:12:52">[00:12:52]</a>. The current, more measured approach offers hope for potentially helping millions of people struggling with health conditions <a class="yt-timestamp" data-t="00:13:09">[00:13:09]</a>.